The  ||| S:0 E:4 ||| DT
β-Blocker  ||| S:4 E:14 ||| JJ
to  ||| S:14 E:17 ||| TO
Lower  ||| S:17 E:23 ||| NNP
Cardiovascular  ||| S:23 E:38 ||| NNP
Dialysis  ||| S:38 E:47 ||| NNP
Events  ||| S:47 E:54 ||| NNP
( ||| S:54 E:55 ||| -LRB-
BLOCADE ||| S:55 E:62 ||| NNP
)  ||| S:62 E:64 ||| -RRB-
Feasibility  ||| S:64 E:76 ||| NNP
Study ||| S:76 E:81 ||| NNP
:  ||| S:81 E:83 ||| :
A  ||| S:83 E:85 ||| DT
Randomized  ||| S:85 E:96 ||| NNP
Controlled  ||| S:96 E:107 ||| NNP
Trial  ||| S:107 E:113 ||| NNP
β-Blocking  ||| S:113 E:124 ||| JJ
agents  ||| S:124 E:131 ||| NNS
reduce  ||| S:131 E:138 ||| VB
cardiovascular  ||| S:138 E:153 ||| JJ
mortality  ||| S:153 E:163 ||| NN
in  ||| S:163 E:166 ||| IN
patients  ||| S:166 E:175 ||| NNS
with  ||| S:175 E:180 ||| IN
heart  ||| S:180 E:186 ||| NN
disease ||| S:186 E:193 ||| NN
,  ||| S:193 E:195 ||| ,
but  ||| S:195 E:199 ||| CC
their  ||| S:199 E:205 ||| PRP$
potential  ||| S:205 E:215 ||| JJ
benefit  ||| S:215 E:223 ||| NN
in  ||| S:223 E:226 ||| IN
dialysis  ||| S:226 E:235 ||| NN
patients  ||| S:235 E:244 ||| NNS
is  ||| S:244 E:247 ||| VBZ
unclear ||| S:247 E:254 ||| JJ
.  ||| S:254 E:256 ||| .
We  ||| S:256 E:259 ||| PRP
aimed  ||| S:259 E:265 ||| VBD
to  ||| S:265 E:268 ||| TO
determine  ||| S:268 E:278 ||| VB
the  ||| S:278 E:282 ||| DT
feasibility  ||| S:282 E:294 ||| NN
of  ||| S:294 E:297 ||| IN
a  ||| S:297 E:299 ||| DT
randomized  ||| S:299 E:310 ||| JJ
controlled  ||| S:310 E:321 ||| JJ
trial  ||| S:321 E:327 ||| NN
( ||| S:327 E:328 ||| -LRB-
RCT ||| S:328 E:331 ||| NNP
) ||| S:331 E:332 ||| -RRB-
.  ||| S:332 E:334 ||| .
Pilot  ||| S:334 E:340 ||| NNP
RCT ||| S:340 E:343 ||| NNP
.  ||| S:343 E:345 ||| .
Patients  ||| S:345 E:354 ||| NNS
who  ||| S:354 E:358 ||| WP
received  ||| S:358 E:367 ||| VBD
dialysis  ||| S:367 E:376 ||| NN
for  ||| S:376 E:380 ||| IN
3  ||| S:380 E:382 ||| CD
or  ||| S:382 E:385 ||| CC
more  ||| S:385 E:390 ||| JJR
months  ||| S:390 E:397 ||| NNS
and  ||| S:397 E:401 ||| CC
were  ||| S:401 E:406 ||| VBD
50  ||| S:406 E:409 ||| CD
years  ||| S:409 E:415 ||| NNS
or  ||| S:415 E:418 ||| CC
older  ||| S:418 E:424 ||| JJR
( ||| S:424 E:425 ||| -LRB-
or ≥18  ||| S:425 E:432 ||| CD
years  ||| S:432 E:438 ||| NNS
with  ||| S:438 E:443 ||| IN
diabetes  ||| S:443 E:452 ||| NN
or  ||| S:452 E:455 ||| CC
cardiovascular  ||| S:455 E:470 ||| JJ
disease ||| S:470 E:477 ||| NN
)  ||| S:477 E:479 ||| -RRB-
were  ||| S:479 E:484 ||| VBD
recruited  ||| S:484 E:494 ||| VBN
from  ||| S:494 E:499 ||| IN
11  ||| S:499 E:502 ||| CD
sites  ||| S:502 E:508 ||| NNS
in  ||| S:508 E:511 ||| IN
Australia  ||| S:511 E:521 ||| NNP
and  ||| S:521 E:525 ||| CC
New  ||| S:525 E:529 ||| NNP
Zealand ||| S:529 E:536 ||| NNP
.  ||| S:536 E:538 ||| .
We  ||| S:538 E:541 ||| PRP
aimed  ||| S:541 E:547 ||| VBD
to  ||| S:547 E:550 ||| TO
recruit  ||| S:550 E:558 ||| VB
150  ||| S:558 E:562 ||| CD
participants ||| S:562 E:574 ||| NNS
.  ||| S:574 E:576 ||| .
After  ||| S:576 E:582 ||| IN
a  ||| S:582 E:584 ||| DT
6-week  ||| S:584 E:591 ||| JJ
run-in  ||| S:591 E:598 ||| NN
with  ||| S:598 E:603 ||| IN
the  ||| S:603 E:607 ||| DT
β-blocker  ||| S:607 E:617 ||| JJ
carvedilol ||| S:617 E:627 ||| NN
,  ||| S:627 E:629 ||| ,
we  ||| S:629 E:632 ||| PRP
randomly  ||| S:632 E:641 ||| RB
assigned  ||| S:641 E:650 ||| VBN
participants  ||| S:650 E:663 ||| NNS
to  ||| S:663 E:666 ||| TO
treatment  ||| S:666 E:676 ||| NN
with  ||| S:676 E:681 ||| IN
carvedilol  ||| S:681 E:692 ||| NN
or  ||| S:692 E:695 ||| CC
placebo  ||| S:695 E:703 ||| NN
for  ||| S:703 E:707 ||| IN
12  ||| S:707 E:710 ||| CD
months ||| S:710 E:716 ||| NNS
.  ||| S:716 E:718 ||| .
The  ||| S:718 E:722 ||| DT
prespecified  ||| S:722 E:735 ||| JJ
primary  ||| S:735 E:743 ||| JJ
outcome  ||| S:743 E:751 ||| NN
was  ||| S:751 E:755 ||| VBD
the  ||| S:755 E:759 ||| DT
proportion  ||| S:759 E:770 ||| NN
of  ||| S:770 E:773 ||| IN
participants  ||| S:773 E:786 ||| NNS
who  ||| S:786 E:790 ||| WP
tolerated  ||| S:790 E:800 ||| VBP
carvedilol ||| S:800 E:810 ||| VBN
,  ||| S:810 E:812 ||| ,
6.25mg ||| S:812 E:818 ||| NNP
,  ||| S:818 E:820 ||| ,
twice  ||| S:820 E:826 ||| RB
daily  ||| S:826 E:832 ||| JJ
during  ||| S:832 E:839 ||| IN
the  ||| S:839 E:843 ||| DT
run-in  ||| S:843 E:850 ||| JJ
period ||| S:850 E:856 ||| NN
.  ||| S:856 E:858 ||| .
After  ||| S:858 E:864 ||| IN
randomization ||| S:864 E:877 ||| NN
,  ||| S:877 E:879 ||| ,
we  ||| S:879 E:882 ||| PRP
report  ||| S:882 E:889 ||| VBP
participant  ||| S:889 E:901 ||| JJ
withdrawal  ||| S:901 E:912 ||| NN
and  ||| S:912 E:916 ||| CC
the  ||| S:916 E:920 ||| DT
incidence  ||| S:920 E:930 ||| NN
of  ||| S:930 E:933 ||| IN
intradialytic  ||| S:933 E:947 ||| JJ
hypotension  ||| S:947 E:959 ||| NNS
( ||| S:959 E:960 ||| -LRB-
IDH ||| S:960 E:963 ||| NNP
) ||| S:963 E:964 ||| -RRB-
.  ||| S:964 E:966 ||| .
Of  ||| S:966 E:969 ||| IN
1,443  ||| S:969 E:975 ||| CD
patients  ||| S:975 E:984 ||| NNS
screened ||| S:984 E:992 ||| VBD
,  ||| S:992 E:994 ||| ,
354  ||| S:994 E:998 ||| CD
were  ||| S:998 E:1003 ||| VBD
eligible ||| S:1003 E:1011 ||| JJ
,  ||| S:1011 E:1013 ||| ,
91  ||| S:1013 E:1016 ||| CD
consented ||| S:1016 E:1025 ||| NN
,  ||| S:1025 E:1027 ||| ,
and  ||| S:1027 E:1031 ||| CC
72  ||| S:1031 E:1034 ||| CD
entered  ||| S:1034 E:1042 ||| VBD
the  ||| S:1042 E:1046 ||| DT
run-in  ||| S:1046 E:1053 ||| JJ
stage.  ||| S:1053 E:1060 ||| CD
49  ||| S:1060 E:1063 ||| CD
of  ||| S:1063 E:1066 ||| IN
72  ||| S:1066 E:1069 ||| CD
run-in  ||| S:1069 E:1076 ||| JJ
participants  ||| S:1076 E:1089 ||| NNS
( ||| S:1089 E:1090 ||| -LRB-
68 ||| S:1090 E:1092 ||| CD
% ||| S:1092 E:1093 ||| NN
;  ||| S:1093 E:1095 ||| :
95 ||| S:1095 E:1097 ||| CD
%  ||| S:1097 E:1099 ||| NN
CI ||| S:1099 E:1101 ||| NNP
,  ||| S:1101 E:1103 ||| ,
57 ||| S:1103 E:1105 ||| CD
% ||| S:1105 E:1106 ||| NN
-79 ||| S:1106 E:1109 ||| CD
% ||| S:1109 E:1110 ||| NN
)  ||| S:1110 E:1112 ||| -RRB-
achieved  ||| S:1112 E:1121 ||| VBD
the  ||| S:1121 E:1125 ||| DT
primary  ||| S:1125 E:1133 ||| JJ
outcome.  ||| S:1133 E:1142 ||| CD
5  ||| S:1142 E:1144 ||| CD
of  ||| S:1144 E:1147 ||| IN
the  ||| S:1147 E:1151 ||| DT
23  ||| S:1151 E:1154 ||| CD
withdrawals  ||| S:1154 E:1166 ||| NNS
from  ||| S:1166 E:1171 ||| IN
run-in  ||| S:1171 E:1178 ||| NNP
were  ||| S:1178 E:1183 ||| VBD
attributable  ||| S:1183 E:1196 ||| JJ
to  ||| S:1196 E:1199 ||| TO
bradycardia  ||| S:1199 E:1211 ||| VB
or  ||| S:1211 E:1214 ||| CC
hypotension ||| S:1214 E:1225 ||| NN
.  ||| S:1225 E:1227 ||| .
After  ||| S:1227 E:1233 ||| IN
randomization ||| S:1233 E:1246 ||| NN
,  ||| S:1246 E:1248 ||| ,
10  ||| S:1248 E:1251 ||| CD
of  ||| S:1251 E:1254 ||| IN
26  ||| S:1254 E:1257 ||| CD
allocated  ||| S:1257 E:1267 ||| VBN
to  ||| S:1267 E:1270 ||| TO
carvedilol  ||| S:1270 E:1281 ||| VB
and  ||| S:1281 E:1285 ||| CC
4  ||| S:1285 E:1287 ||| CD
of  ||| S:1287 E:1290 ||| IN
23  ||| S:1290 E:1293 ||| CD
allocated  ||| S:1293 E:1303 ||| VBN
to  ||| S:1303 E:1306 ||| TO
placebo  ||| S:1306 E:1314 ||| CD
withdrew.  ||| S:1314 E:1324 ||| CD
4  ||| S:1324 E:1326 ||| CD
participants  ||| S:1326 E:1339 ||| NNS
randomly  ||| S:1339 E:1348 ||| RB
assigned  ||| S:1348 E:1357 ||| VBN
to  ||| S:1357 E:1360 ||| TO
carvedilol  ||| S:1360 E:1371 ||| VB
withdrew  ||| S:1371 E:1380 ||| VBN
because  ||| S:1380 E:1388 ||| IN
of  ||| S:1388 E:1391 ||| IN
bradycardia  ||| S:1391 E:1403 ||| NN
or  ||| S:1403 E:1406 ||| CC
hypotension ||| S:1406 E:1417 ||| NN
.  ||| S:1417 E:1419 ||| .
Overall ||| S:1419 E:1426 ||| RB
,  ||| S:1426 E:1428 ||| ,
there  ||| S:1428 E:1434 ||| EX
were  ||| S:1434 E:1439 ||| VBD
4  ||| S:1439 E:1441 ||| CD
IDH  ||| S:1441 E:1445 ||| NN
events  ||| S:1445 E:1452 ||| NNS
per  ||| S:1452 E:1456 ||| IN
100  ||| S:1456 E:1460 ||| CD
hemodialysis  ||| S:1460 E:1473 ||| CD
sessions ||| S:1473 E:1481 ||| NNS
;  ||| S:1481 E:1483 ||| :
in  ||| S:1483 E:1486 ||| IN
participants  ||| S:1486 E:1499 ||| NNS
allocated  ||| S:1499 E:1509 ||| VBN
to  ||| S:1509 E:1512 ||| TO
carvedilol  ||| S:1512 E:1523 ||| FW
versus  ||| S:1523 E:1530 ||| FW
placebo ||| S:1530 E:1537 ||| FW
,  ||| S:1537 E:1539 ||| ,
respectively ||| S:1539 E:1551 ||| RB
,  ||| S:1551 E:1553 ||| ,
there  ||| S:1553 E:1559 ||| EX
were  ||| S:1559 E:1564 ||| VBD
7  ||| S:1564 E:1566 ||| CD
versus  ||| S:1566 E:1573 ||| CD
2  ||| S:1573 E:1575 ||| CD
IDH  ||| S:1575 E:1579 ||| NN
events  ||| S:1579 E:1586 ||| NNS
per  ||| S:1586 E:1590 ||| IN
100  ||| S:1590 E:1594 ||| CD
hemodialysis  ||| S:1594 E:1607 ||| CD
sessions  ||| S:1607 E:1616 ||| NNS
( ||| S:1616 E:1617 ||| -LRB-
P=0.1 ||| S:1617 E:1622 ||| NNP
)  ||| S:1622 E:1624 ||| -RRB-
in  ||| S:1624 E:1627 ||| IN
the  ||| S:1627 E:1631 ||| DT
2  ||| S:1631 E:1633 ||| CD
weeks  ||| S:1633 E:1639 ||| NNS
immediately  ||| S:1639 E:1651 ||| RB
following  ||| S:1651 E:1661 ||| VBG
a  ||| S:1661 E:1663 ||| DT
dose  ||| S:1663 E:1668 ||| NN
increase  ||| S:1668 E:1677 ||| NN
and  ||| S:1677 E:1681 ||| CC
4  ||| S:1681 E:1683 ||| CD
versus  ||| S:1683 E:1690 ||| CD
3  ||| S:1690 E:1692 ||| CD
IDH  ||| S:1692 E:1696 ||| NN
events  ||| S:1696 E:1703 ||| NNS
per  ||| S:1703 E:1707 ||| IN
100  ||| S:1707 E:1711 ||| CD
hemodialysis  ||| S:1711 E:1724 ||| CD
sessions  ||| S:1724 E:1733 ||| NNS
after  ||| S:1733 E:1739 ||| IN
no  ||| S:1739 E:1742 ||| DT
dose  ||| S:1742 E:1747 ||| NN
increase  ||| S:1747 E:1756 ||| NN
( ||| S:1756 E:1757 ||| -LRB-
P=0.7 ||| S:1757 E:1762 ||| NNP
) ||| S:1762 E:1763 ||| -RRB-
.  ||| S:1763 E:1765 ||| .
Unable  ||| S:1765 E:1772 ||| JJ
to  ||| S:1772 E:1775 ||| TO
recruit  ||| S:1775 E:1783 ||| VB
planned  ||| S:1783 E:1791 ||| JJ
sample  ||| S:1791 E:1798 ||| NN
size ||| S:1798 E:1802 ||| NN
.  ||| S:1802 E:1804 ||| .
Recruiting  ||| S:1804 E:1815 ||| VBG
patients  ||| S:1815 E:1824 ||| NNS
receiving  ||| S:1824 E:1834 ||| VBG
dialysis  ||| S:1834 E:1843 ||| NN
to  ||| S:1843 E:1846 ||| TO
an  ||| S:1846 E:1849 ||| DT
RCT  ||| S:1849 E:1853 ||| NNP
of  ||| S:1853 E:1856 ||| IN
β-blocker  ||| S:1856 E:1866 ||| FW
versus  ||| S:1866 E:1873 ||| FW
placebo  ||| S:1873 E:1881 ||| FW
will  ||| S:1881 E:1886 ||| MD
prove  ||| S:1886 E:1892 ||| VB
challenging ||| S:1892 E:1903 ||| VBG
.  ||| S:1903 E:1905 ||| .
Possible  ||| S:1905 E:1914 ||| JJ
solutions  ||| S:1914 E:1924 ||| NNS
include  ||| S:1924 E:1932 ||| VBP
international  ||| S:1932 E:1946 ||| JJ
collaboration  ||| S:1946 E:1960 ||| NN
and  ||| S:1960 E:1964 ||| CC
exploring  ||| S:1964 E:1974 ||| VBG
novel  ||| S:1974 E:1980 ||| NN
trial  ||| S:1980 E:1986 ||| NN
designs  ||| S:1986 E:1994 ||| VBZ
such  ||| S:1994 E:1999 ||| JJ
as  ||| S:1999 E:2002 ||| IN
a  ||| S:2002 E:2004 ||| DT
registry-based  ||| S:2004 E:2019 ||| JJ
RCT ||| S:2019 E:2022 ||| NNP
.  ||| S:2022 E:2024 ||| .
